Shineco (SISI) Ignites Growth: $8.7M Tech Deal & Major Singapore Alliance Unleash Dual Engines
Rhea-AI Summary
Shineco (NASDAQ: SISI) has announced two major strategic developments in its biocellular technology business. First, its subsidiary Dong'ao Health secured a $8.7 million technology services contract with Xinke Future Biotechnology for developing microalgae-derived extracellular vesicles technology, with an initial payment of $560,000 already received. The contract runs from August 2025 to December 2026.
Second, Shineco formed a strategic alliance with Singapore's BICC, following a high-level delegation visit. The partnership includes establishing a joint laboratory, implementing technology exchange mechanisms, and integrating BICC's 3,000+ Southeast Asian agents with Dong'ao Health's domestic wellness channels. The collaboration aims to develop stem cell transfusion centers and standardized clinical services.
Positive
- Secured $8.7 million technology services contract with clear payment milestones
- Initial payment of $560,000 already received
- Strategic partnership with BICC provides access to 3,000+ agents in Southeast Asia
- Development of multiple revenue streams through 'develop once, deploy multiple times' technology model
Negative
- Long development timeline extending to December 2026
- Success dependent on achieving R&D milestones for subsequent payments
- Significant investment required in joint laboratory and infrastructure development
News Market Reaction – SISI
On the day this news was published, SISI gained 0.50%, reflecting a mild positive market reaction. Argus tracked a peak move of +3.8% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $31K to the company's valuation, bringing the market cap to $6M at that time.
Data tracked by StockTitan Argus on the day of publication.
As the core entity executing Shineco's strategy in the biocellular market, Dong'ao Health's new contract focuses on cutting-edge microalgae-derived extracellular vesicles technology. The service period runs from August 25, 2025, to December 31, 2026, with the goal of building a comprehensive, end-to-end R&D system from basic research to process development and product translation. Specific tasks include functional validation during the basic research phase; breaking bottlenecks in large-scale (e.g., hectoliter-scale) separation and extraction processes to achieve mass production; and developing at least two therapeutic products with full regulatory support to effectively transition the technology from the lab to the market.
This contract provides clear near-term financial momentum for Shineco. The total value of
"This contract is a powerful validation of our strategy to monetize cutting-edge research and create near-term revenue," said Jennifer Zhan, CEO of Shineco. "Coupled with our strategic alliance with BICC, it provides two clear, synergistic engines for growth that strengthen our domestic business while accelerating our international expansion."
Concurrent with this R&D progress, Shineco's international cooperation achieved a key milestone. BICC sent a high-level delegation to Dong'ao Health from September 6-10, including Chairman Mr. Yang Shengnan, CEO Ms. Barbara Tan, CFO Mr. Jon Lim, Chief Scientist Mr. Chen Yanming, and shareholder Mr. Chen Laifu.
The delegation conducted on-site inspections of Dong'ao Health's four core segments—the Health and Wellness Center, Cell R&D Center, under-construction Alzheimer's Disease Care Town, and partner "Anhe Meige Medical Aesthetic Hospital"—to evaluate potential synergies. The parties agreed to establish a joint laboratory, implement a technology exchange mechanism, integrate BICC's network of over 3,000 agents in
These dual developments exemplify Shineco's two-pronged strategy of "technology development plus ecosystem synergy." Technologically, the partnership combines complementary R&D capabilities and application scenarios. From a market perspective, the contracted revenue and BICC's international channels create a strategy of "a solid domestic base + expansion into new international markets." Financially, the deal improves short-term cash flow and enhances long-term profitability through technology leverage and market expansion.
"These advancements demonstrate the effective operation of our complete value chain from technology to industry to capital," CEO Jennifer Zhan emphasized. "Shineco remains committed to deepening our technology industrialization efforts and advancing international partnerships to deliver sustainable returns for our shareholders."
Shineco will provide regular updates on the contract's execution and the collaboration with BICC in accordance with NASDAQ disclosure rules.
About Xi'an Dong'ao Health Management Co., Ltd.
Xi'an Dong'ao Health provides GMP-compliant biostorage and clinical cell applications, delivering integrated health management via "Prevention-Intervention-Maintenance" protocols.
About BICC Pte Ltd
BICC Pte Ltd is a
About Shineco, Inc.
Shineco, Inc. is dedicated to improving quality of life through the development and provision of safe, efficient, and high-quality health and medical products and services. The Company's core business focuses on induced pluripotent stem cell (iPSC) technology platforms and extracellular vesicle-derived products. For more information, please visit www.biosisi.com.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by words such as "may," "will," "should," "could," "intend," "expect," "plan," "budget," "forecast," "anticipate," "believe," "estimate," "forecast," "potential," "continue," "evaluate" or similar words. Forward-looking statements should not be relied upon as they are neither historical facts nor guarantees of future performance. Rather, they are based solely on our current beliefs, expectations and assumptions about future business, future plans and strategies, forecasts, expected events and trends, economics, and other future conditions. Examples of forward-looking statements include, among other things, our innovation and market position in our products and services, our competitive advantages, and our expectation that the 5-minute cardiac test will be one of the leading products in this field to meet the need for test results immediately upon intake. Please do not rely on any forward-looking statements. Actual results may differ materially from those indicated in historical results or forward-looking statements due to various factors, including, but not limited to, the Company's ability to raise additional capital, its ability to maintain and grow its business, the variability of its results of operations, its ability to maintain and enhance its brand, its ability to develop and introduce new products and services, its ability to obtain all necessary regulatory approvals in the jurisdictions in which it intends to market and sell its products, companies to be acquired, successful integration of technology and assets into its portfolio of products and services, marketing and other business development initiatives, industry competition, general government regulations, economic conditions, impact of the COVID-19 pandemic, reliance on key personnel, attracting, hiring and retaining personnel with the technical skills and experience required to meet customer requirements and protecting its intellectual property. Shineco encourages you to review these and other factors that may affect its future performance in its filings with the Securities and Exchange Commission. The forward-looking statements in this press release are based only on information currently available to us and are made only as of the date of this press release, and Shineco undertakes no obligation to update any forward-looking statements, except as required by applicable rules and regulations.
For more information, please contact:
Shineco, Inc.
Email: secretary@shineco.tech
Phone: +86-10-68130220
View original content:https://www.prnewswire.com/news-releases/shineco-sisi-ignites-growth-8-7m-tech-deal--major-singapore-alliance-unleash-dual-engines-302554831.html
SOURCE Shineco,Inc.
FAQ
What is the value of Shineco's (SISI) new technology services contract?
What is the partnership between Shineco (SISI) and BICC?
How long is Shineco's (SISI) new technology development contract?
What are the main business segments of Shineco's (SISI) Dong'ao Health subsidiary?
How will the BICC partnership benefit Shineco (SISI)?
